Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition - Headlines news and analysis from Global Banking & Finance Review

Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Headlines

Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition

Published by Global Banking & Finance Review

Posted on April 18, 2025

1 min read

· Last updated: April 18, 2025

Add as preferred source on Google

FDA Approves Extended Use of Dupixent for Skin Condition

(Reuters) -The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.

(Reporting by Christy Santhosh and Gnaneshwar Rajan in Bengaluru; Editing by Alison Williams)

Key Takeaways

FDA approves Dupixent for extended use.
Sanofi and Regeneron collaborate on Dupixent.
Dupixent targets a specific skin condition.
Approval marks a significant milestone.
Regulatory news impacts pharmaceutical sector.

Frequently Asked Questions

What is the main topic?

The main topic is the FDA's approval of Sanofi and Regeneron's drug Dupixent for extended use in treating a skin condition.

What companies are involved?

Sanofi and Regeneron are the companies involved in the development and approval of Dupixent.

What is Dupixent used for?

Dupixent is used for treating certain skin conditions and has now received FDA approval for extended use.

UK lawmaker resigns seat, clearing path for leadership challenger Burnham

Five Italians die in Maldives diving incident, foreign ministry says

Gaza aid flotilla sets sail again after Israeli interceptions

King Charles visits Jewish area of London hit by antisemitic attacks

From ally to rival, Wes Streeting turns on UK PM Starmer

Outcry in Italy over plans to expand Rome's famed Borghese Gallery

More from Headlines

Explore more articles in the Headlines category

Denmark's Queen Margrethe admitted to hospital

UK's Princess Kate learns pasta-making on visit to Italy

Tracey Emin debuts intimate new prints at London art fair

Lebanon to press Israel to cease fire at Washington talks, Lebanese official says

Israeli nationalists hold parade marking their capture of East Jerusalem

Prince Harry says antisemitism in UK is "deeply troubling"

Latvian Prime Minister Silina says she is resigning

UK police charge second man over arson at former synagogue

Ukraine's anti-corruption court places Zelenskiy's former chief of staff Yermak under arrest

French central bank succession fight tests Macron's sway ahead of 2027 election

Cricket-Former England women's stumper Taylor named men's fielding coach for NZ series

English voters where Labour lost say PM Starmer has to go

View All Headlines Posts